1
|
Cordeiro MF, Denis P, Astarita C, Belsey J, Rivas M, García-Feijoo J. Prevalence of comorbidities with the potential to increase the risk of nonadherence to topical ocular hypotensive medication in patients with open-angle glaucoma. Curr Med Res Opin 2024; 40:647-655. [PMID: 38410906 DOI: 10.1080/03007995.2024.2322048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Accepted: 02/19/2024] [Indexed: 02/28/2024]
Abstract
OBJECTIVE To evaluate the prevalence of comorbidities that may limit or prevent adherence to topical ocular hypotensive therapy in patients with open-angle glaucoma (OAG). METHODS The UK Clinical Practice Research Datalink (CPRD) database of primary and secondary care and prescription records was analyzed to identify patients with a first (index) diagnosis of OAG during 2016-2020. The primary care records of these patients were screened for diagnostic terms linked to prespecified (qualifying) comorbidities considered to have the potential to impact patients' ability to instill eye drops. The prevalence of each of 10 categories of qualifying comorbidity recorded within the period from 5 years before to 2 years after the index OAG diagnosis was analyzed. RESULTS A total of 100,968 patients with OAG were included in the analysis. Among the patients in the OAG cohort, 13,962 (13.8%) were aged 40-54 years, 32,145 (31.8%) were aged 55-69 years, 42,042 (41.6%) were aged 70-84 years, and 12,819 (12.7%) were aged 85+ years. Within the OAG population, 82.7%, 14.6%, and 2.7% of patients had no category, one category, and two or more categories of qualifying comorbidity, respectively. Qualifying comorbidities were most common in older patients. The most prevalent qualifying comorbidities were categorized as degenerative, traumatic, or pathological central nervous system disorder disrupting cognitive function (5.2%), movement disorder (4.4%), and low vision (4.1%). The prevalence of arthropathies and injuries affecting upper limbs (including arthritis in the hands) was 2.4%. CONCLUSIONS The presence of comorbidities should be considered when determining whether eye drops are suitable treatment for glaucoma. Neurodegenerative disease affecting cognition and memory, motor disease, and low vision are common comorbidities that may impact adherence to eye drops, and affected patients may benefit from non-drop treatment modalities.
Collapse
Affiliation(s)
- M Francesca Cordeiro
- Imperial College Ophthalmic Research Group (ICORG), Imperial College London, London, UK
- Glaucoma & Retinal Neurodegeneration Research Group, Institute of Ophthalmology, University College London, London, UK
| | - Philippe Denis
- Service d'Ophtalmologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | | | | | | | - Julián García-Feijoo
- Department of Ophthalmology, San Carlos Clinical Hospital, UCM, Instituto de Investigaciones Oftalmologicas Ramon Castroviejo, Madrid, Spain
| |
Collapse
|
2
|
Kerckhove N, Bornier N, Mulliez A, Elyn A, Teixeira S, Authier N, Bertin C, Chenaf C. Prevalence of Chronic Pain Among People with Dementia: A Nationwide Study Using French Administrative Data. Am J Geriatr Psychiatry 2023; 31:1149-1163. [PMID: 37468390 DOI: 10.1016/j.jagp.2023.06.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Revised: 06/02/2023] [Accepted: 06/24/2023] [Indexed: 07/21/2023]
Abstract
OBJECTIVE Alzheimer's disease or Related Dementia (ADRD) is known to disturb pain perception and reduce the ability to report it, resulting in underestimation by practitioners and sub-optimal medical management. The aim of this study was to estimate the prevalence of all types of CP among people with ADRD. DESIGN Nationwide cross-sectional study. SETTINGS French community-dwelling and nursing home residents. PARTICIPANTS People with ADRD, >40 years old, treated with cholinesterase inhibitors or memantine, or with a diagnosis/long-term illness of ADRD and matched with a comparison sample. SETTINGS French community-dwelling and nursing home residents. PARTICIPANTS People with ADRD, >40 years old, treated with cognitive stimulants (cholinesterase inhibitors and memantine) or with a diagnosis/long-term illness of ADRD and matched with a comparison sample (non-ADRD). MEASUREMENTS The capture-recapture method was performed to provide estimates of the prevalence of CP. People treated with analgesic drugs for ≥6 months consecutively or with a medical diagnosis of CP (ICD-10 codes) or referred to a pain center were considered as having CP. RESULTS A total of 48,288 individuals were included, of which 16,096 had ADRD and 32,192 without ADRD. The estimated prevalence of CP in people with ADRD was from 57.7% [52.9;63.3] to 57.9%[53.0;63.9], and slightly higher than the non-ADRD sample (from 49.9%[47.0;53.2] to 50.4%[47.3;53.9], p <0.001). CONCLUSIONS The prevalence of CP among people living with ADRD was at least the same as or better than individuals without ADRD. This result should alert practitioners' attention to the need for effective pain assessment and management in this population who has difficulties to express and feel pain.
Collapse
Affiliation(s)
- Nicolas Kerckhove
- Service de Pharmacologie médicale (NK, NB, ST, NA, CB, CC), Centres Addictovigilance et Pharmacovigilance, Centre d'Evaluation et de Traitement de la Douleur, Université Clermont Auvergne, CHU Clermont-Ferrand, INSERM, NEURO-DOL, F-63000 Clermont-Ferrand, France; Université Clermont Auvergne (NK, NA, CB, CC), Institut Analgesia, Clermont-Ferrand, France.
| | - Nadège Bornier
- Service de Pharmacologie médicale (NK, NB, ST, NA, CB, CC), Centres Addictovigilance et Pharmacovigilance, Centre d'Evaluation et de Traitement de la Douleur, Université Clermont Auvergne, CHU Clermont-Ferrand, INSERM, NEURO-DOL, F-63000 Clermont-Ferrand, France
| | - Aurélien Mulliez
- Direction de la recherche clinique et de l'innovation (AM), Clermont-Ferrand, France
| | - Antoine Elyn
- Centre d'Évaluation et de Traitement de la Douleur (AE), Service de Neurochirurgie, Pôle Neuroscience, Hôpital Purpan, Pierre Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Place du Dr Joseph Baylac, Toulouse, France; RECaP F-CRIN, Groupe « Soins Primaires » (AE), Réseau national de Recherche en Épidémiologie Clinique et en Santé Publique, Inserm, France
| | - Sarah Teixeira
- Service de Pharmacologie médicale (NK, NB, ST, NA, CB, CC), Centres Addictovigilance et Pharmacovigilance, Centre d'Evaluation et de Traitement de la Douleur, Université Clermont Auvergne, CHU Clermont-Ferrand, INSERM, NEURO-DOL, F-63000 Clermont-Ferrand, France
| | - Nicolas Authier
- Service de Pharmacologie médicale (NK, NB, ST, NA, CB, CC), Centres Addictovigilance et Pharmacovigilance, Centre d'Evaluation et de Traitement de la Douleur, Université Clermont Auvergne, CHU Clermont-Ferrand, INSERM, NEURO-DOL, F-63000 Clermont-Ferrand, France; Université Clermont Auvergne (NK, NA, CB, CC), Institut Analgesia, Clermont-Ferrand, France; Observatoire Français des Médicaments Antalgiques (OFMA) (NA, CB, CC), Université Clermont Auvergne, Clermont-Ferrand, France
| | - Célian Bertin
- Service de Pharmacologie médicale (NK, NB, ST, NA, CB, CC), Centres Addictovigilance et Pharmacovigilance, Centre d'Evaluation et de Traitement de la Douleur, Université Clermont Auvergne, CHU Clermont-Ferrand, INSERM, NEURO-DOL, F-63000 Clermont-Ferrand, France; Université Clermont Auvergne (NK, NA, CB, CC), Institut Analgesia, Clermont-Ferrand, France; Observatoire Français des Médicaments Antalgiques (OFMA) (NA, CB, CC), Université Clermont Auvergne, Clermont-Ferrand, France
| | - Chouki Chenaf
- Service de Pharmacologie médicale (NK, NB, ST, NA, CB, CC), Centres Addictovigilance et Pharmacovigilance, Centre d'Evaluation et de Traitement de la Douleur, Université Clermont Auvergne, CHU Clermont-Ferrand, INSERM, NEURO-DOL, F-63000 Clermont-Ferrand, France; Université Clermont Auvergne (NK, NA, CB, CC), Institut Analgesia, Clermont-Ferrand, France; Observatoire Français des Médicaments Antalgiques (OFMA) (NA, CB, CC), Université Clermont Auvergne, Clermont-Ferrand, France
| |
Collapse
|
3
|
Yang F, Wu Y, Hockey R, Doust J, Mishra GD, Montgomery GW, Mortlock S. Evidence of shared genetic factors in the etiology of gastrointestinal disorders and endometriosis and clinical implications for disease management. Cell Rep Med 2023; 4:101250. [PMID: 37909040 PMCID: PMC10694629 DOI: 10.1016/j.xcrm.2023.101250] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2022] [Revised: 03/26/2023] [Accepted: 09/27/2023] [Indexed: 11/02/2023]
Abstract
In clinical practice, the co-existence of endometriosis and gastrointestinal symptoms is often observed. Using large-scale datasets, we report a genetic correlation between endometriosis and irritable bowel syndrome (IBS), peptic ulcer disease (PUD), gastro-esophageal reflux disease (GORD), and a combined GORD/PUD medicated (GPM) phenotype. Mendelian randomization analyses support a causal relationship between genetic predisposition to endometriosis and IBS and GPM. Identification of shared risk loci highlights biological pathways that may contribute to the pathogenesis of both diseases, including estrogen regulation and inflammation, and potential therapeutic drug targets (CCKBR; PDE4B). Higher use of IBS, GORD, and PUD medications in women with endometriosis and higher use of hormone therapies in women with IBS, GORD, and PUD, support the co-occurrence of these conditions and highlight the potential for drug repositioning and drug contraindications. Our results provide evidence of shared disease etiology and have important clinical implications for diagnostic and treatment decisions for both diseases.
Collapse
Affiliation(s)
- Fei Yang
- The Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia
| | - Yeda Wu
- The Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia
| | - Richard Hockey
- The University of Queensland, NHMRC Centre for Research Excellence on Women and Non-communicable Diseases (CREWaND), School of Public Health, Herston Road, Herston, QLD, Australia
| | - Jenny Doust
- The University of Queensland, NHMRC Centre for Research Excellence on Women and Non-communicable Diseases (CREWaND), School of Public Health, Herston Road, Herston, QLD, Australia
| | - Gita D Mishra
- The University of Queensland, NHMRC Centre for Research Excellence on Women and Non-communicable Diseases (CREWaND), School of Public Health, Herston Road, Herston, QLD, Australia
| | - Grant W Montgomery
- The Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia
| | - Sally Mortlock
- The Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia.
| |
Collapse
|
4
|
Bornier N, Mulliez A, Chenaf C, Elyn A, Teixeira S, Authier N, Bertin C, Kerckhove N. Chronic pain is a risk factor for incident Alzheimer's disease: a nationwide propensity-matched cohort using administrative data. Front Aging Neurosci 2023; 15:1193108. [PMID: 37842123 PMCID: PMC10575742 DOI: 10.3389/fnagi.2023.1193108] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Accepted: 08/29/2023] [Indexed: 10/17/2023] Open
Abstract
Introduction Chronic pain (CP) is one of the most disabling conditions in the elderly and seems to be a risk factor for the development of Alzheimer's disease and related dementias (ADRD). Only one study, using national administrative health databases, assessed and demonstrated that chronic pain (all types of pain) was a risk factor for dementia, but without assessing the impact of pain medications. Method To assess the impact of all types of chronic pain and the long-term use of pain medications on the person-years incidence of ADRD, a retrospective nationwide healthcare administrative data study was performed using the national inter-regime health insurance information system (SNIIRAM) to the French national health data system (SNDS). Incident people >50 years old with chronic pain, defined by at least 6-months duration analgesics treatment or by a diagnosis/long-term illness of chronic pain between 2006 and 2010, were included. Chronic pain individuals were matched with non-CP individuals by a propensity score. Individuals were followed up from 9 to 13 years to identify occurrences of ADRD from 2006. Results Among 64,496 French individuals, the incidence of ADRD was higher in the chronic pain population than control (1.13% vs. 0.95%, p <0.001). Chronic pain increases the risk of ADRD (HR = 1.23) and the incidence of ADRD was higher for women and increased significantly with age. Discussion Our study highlights the importance of prevention, diagnosis, and management of chronic pain in elderly to reduce the risk of development and/or worsening of dementia.
Collapse
Affiliation(s)
- Nadège Bornier
- Service de Pharmacologie Médicale, Direction de la Recherche Clinique et de L’Innovation, Université Clermont Auvergne, Clermont-Ferrand, France
| | - Aurélien Mulliez
- Service de Pharmacologie Médicale, Direction de la Recherche Clinique et de L’Innovation, Université Clermont Auvergne, Clermont-Ferrand, France
| | - Chouki Chenaf
- Service de Pharmacologie Médicale, Direction de la Recherche Clinique et de L’Innovation, Université Clermont Auvergne, Clermont-Ferrand, France
- Institut Analgesia, Clermont-Ferrand, France
| | - Antoine Elyn
- Centre D’Évaluation et de Traitement de la Douleur, Service de Neurochirurgie, Pôle Neuroscience, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Sarah Teixeira
- Service de Pharmacologie Médicale, Direction de la Recherche Clinique et de L’Innovation, Université Clermont Auvergne, Clermont-Ferrand, France
| | - Nicolas Authier
- Service de Pharmacologie Médicale, Direction de la Recherche Clinique et de L’Innovation, Université Clermont Auvergne, Clermont-Ferrand, France
- Institut Analgesia, Clermont-Ferrand, France
| | - Célian Bertin
- Service de Pharmacologie Médicale, Direction de la Recherche Clinique et de L’Innovation, Université Clermont Auvergne, Clermont-Ferrand, France
- Institut Analgesia, Clermont-Ferrand, France
| | - Nicolas Kerckhove
- Service de Pharmacologie Médicale, Direction de la Recherche Clinique et de L’Innovation, Université Clermont Auvergne, Clermont-Ferrand, France
- Institut Analgesia, Clermont-Ferrand, France
| |
Collapse
|
5
|
Fišar Z. Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer's Disease and Identifying Promising Drug Targets. Biomolecules 2022; 12:1676. [PMID: 36421690 PMCID: PMC9687482 DOI: 10.3390/biom12111676] [Citation(s) in RCA: 23] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 10/23/2022] [Accepted: 11/09/2022] [Indexed: 08/27/2023] Open
Abstract
Damage or loss of brain cells and impaired neurochemistry, neurogenesis, and synaptic and nonsynaptic plasticity of the brain lead to dementia in neurodegenerative diseases, such as Alzheimer's disease (AD). Injury to synapses and neurons and accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles are considered the main morphological and neuropathological features of AD. Age, genetic and epigenetic factors, environmental stressors, and lifestyle contribute to the risk of AD onset and progression. These risk factors are associated with structural and functional changes in the brain, leading to cognitive decline. Biomarkers of AD reflect or cause specific changes in brain function, especially changes in pathways associated with neurotransmission, neuroinflammation, bioenergetics, apoptosis, and oxidative and nitrosative stress. Even in the initial stages, AD is associated with Aβ neurotoxicity, mitochondrial dysfunction, and tau neurotoxicity. The integrative amyloid-tau-mitochondrial hypothesis assumes that the primary cause of AD is the neurotoxicity of Aβ oligomers and tau oligomers, mitochondrial dysfunction, and their mutual synergy. For the development of new efficient AD drugs, targeting the elimination of neurotoxicity, mutual potentiation of effects, and unwanted protein interactions of risk factors and biomarkers (mainly Aβ oligomers, tau oligomers, and mitochondrial dysfunction) in the early stage of the disease seems promising.
Collapse
Affiliation(s)
- Zdeněk Fišar
- Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 11, 120 00 Prague, Czech Republic
| |
Collapse
|
6
|
Ali Babar B, Vu M, Koponen M, Taipale H, Tanskanen A, Kettunen R, Tiihonen M, Hartikainen S, Tolppanen AM. Prevalence of oral anticoagulant use among people with and without Alzheimer’s disease. BMC Geriatr 2022; 22:464. [PMID: 35643439 PMCID: PMC9148467 DOI: 10.1186/s12877-022-03144-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Accepted: 05/18/2022] [Indexed: 11/29/2022] Open
Abstract
Background Although cardio- and cerebrovascular diseases are common among people with Alzheimer’s disease (AD), it is unknown how the prevalence of oral anticoagulant (OAC) use changes in relation to AD diagnosis. We investigated the prevalence of OAC use in relation to AD diagnosis in comparison to a matched cohort without AD. Methods Register-based Medication use and Alzheimer’s disease (MEDALZ) cohort includes 70 718 Finnish people with AD diagnosed between 2005–2011. Point prevalence of OAC use (prescription register) was calculated every three months with three-month evaluation periods, from five years before to five years after clinically verified diagnosis and compared to matched cohort without AD. Longitudinal association between AD and OAC use was evaluated by generalized estimating equations (GEE). Results OAC use was more common among people with AD until AD diagnosis, (OR 1.17; 95% CI 1.13–1.22), and less common after AD diagnosis (OR 0.87; 95% CI 0.85–0.89), compared to people without AD. At the time of AD diagnosis, prevalence was 23% and 20% among people with and without AD, respectively. OAC use among people with AD began to decline gradually two years after AD diagnosis while continuous increase was observed in the comparison cohort. Warfarin was the most common OAC, and atrial fibrillation was the most common comorbidity in OAC users. Conclusion Decline in OAC use among people with AD after diagnosis may be attributed to high risk of falling and problems in monitoring. However, direct oral anticoagulants (DOACs) that are nowadays more commonly used require less monitoring and may also be safer for vulnerable people with AD. Supplementary Information The online version contains supplementary material available at 10.1186/s12877-022-03144-x.
Collapse
|
7
|
Gao Y, Zhang N, Lv C, Li N, Li X, Li W. lncRNA SNHG1 Knockdown Alleviates Amyloid-β-Induced Neuronal Injury by Regulating ZNF217 via Sponging miR-361-3p in Alzheimer's Disease. J Alzheimers Dis 2021; 77:85-98. [PMID: 32741808 DOI: 10.3233/jad-191303] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND Long noncoding RNAs have been proven to play an important role in the progression of Alzheimer's disease (AD). However, the function of small nucleolar RNA host gene 1 (SNHG1) in AD progression remains to be studied. OBJECTIVE To explore the role of SNHG1 in AD progression and clarify its potential mechanism. METHODS Amyloid β-protein (Aβ) was used to construct an AD cell model in vitro. The expression levels of SNHG1 and miR-361-3p were determined by quantitative real-time polymerase chain reaction. Cell viability and apoptosis were measured by cell counting kit 8 assay and flow cytometry. The levels of apoptosis-related proteins and zinc finger gene 217 (ZNF217) protein were evaluated by western blot analysis. Additionally, the contents of inflammatory cytokines and oxidative stress markers were tested by enzyme-linked immunosorbent assay. Furthermore, dual-luciferase reporter and RNA immunoprecipitation assays were used to verify the interaction between miR-361-3p and SNHG1 or ZNF217. RESULTS Aβ could induce cell injury, while resveratrol could reverse this effect. SNHG1 expression was positively regulated by Aβ and negatively regulated by resveratrol. SNHG1 knockdown could reverse the promotion effect of Aβ on cell injury. Moreover, SNHG1 sponged miR-361-3p, and miR-361-3p targeted ZNF217. Additionally, miR-361-3p overexpression reversed the promotion effect of SNHG1 overexpression on cell injury, and ZNF217 silencing also reversed the promotion effect of miR-361-3p inhibitor on cell injury. CONCLUSION SNHG1 promoted cell injury by regulating the miR-361-3p/ZNF217 axis, which might provide a theoretical basis for molecular therapy of AD.
Collapse
Affiliation(s)
- Yiwen Gao
- Department of Pharmacy, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, China
| | - Nan Zhang
- Department of Geriatrics, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, China
| | - Chunmei Lv
- Department of Pharmacy, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, China
| | - Na Li
- Department of Rehabilitation, The People's Hospital of Qingdao Shinan District, Qingdao, Shandong, China
| | - Xueqin Li
- Department of Pharmacy, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, China
| | - Weiwei Li
- Department of Neurology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, China
| |
Collapse
|
8
|
Voronkov M, Ataiants J, Cocchiaro B, Stock JB, Lankenau SE. A vicious cycle of neuropathological, cognitive and behavioural sequelae of repeated opioid overdose. THE INTERNATIONAL JOURNAL OF DRUG POLICY 2021; 97:103362. [PMID: 34314956 DOI: 10.1016/j.drugpo.2021.103362] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2021] [Revised: 05/03/2021] [Accepted: 06/23/2021] [Indexed: 01/15/2023]
Abstract
In the midst of an escalating U.S. opioid crisis, the immediate focus of public health interventions is on fatal overdose prevention. Few studies, however, have sought to examine the long-term health consequences of exposure to repeated nonfatal opioid overdose. We reviewed recent literature to examine three corresponding downstream health outcomes of repeated overdose: a) neurodegenerative processes; b) cognition and memory; and c) overdose risk behaviours. We found a remarkable congruency among available biochemical and cognitive data on how nonfatal overdose precipitates various pathological feedforward and feedback loops that affect people who use opioids for years to come. We found however that downstream behavioural implications of neurodegenerative and cognitive sequelae are less studied despite being most proximal to an overdose. Findings point to a vicious cycle of nonfatal overdose leading to neurodegeneration - closely resembling Alzheimer Disease - that results in cognitive decline that in turn leads to potentially reduced adherence to safe drug use behaviours. The collected evidence not only brings into the focus the long-term health consequences of nonfatal overdose from the perspectives of biology, neuroscience, and public health, but also creates new cross-disciplinary context and awareness in the research and public health community that should benefit people at risk.
Collapse
Affiliation(s)
| | - Janna Ataiants
- Dornsife School of Public Health, Drexel University, Philadelphia, PA 19104, USA.
| | - Benjamin Cocchiaro
- Center for Public Health Initiatives, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Jeffry B Stock
- Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA
| | - Stephen E Lankenau
- Dornsife School of Public Health, Drexel University, Philadelphia, PA 19104, USA
| |
Collapse
|
9
|
Jia J, Xu J, Liu J, Wang Y, Wang Y, Cao Y, Guo Q, Qu Q, Wei C, Wei W, Zhang J, Yu E. Comprehensive Management of Daily Living Activities, behavioral and Psychological Symptoms, and Cognitive Function in Patients with Alzheimer's Disease: A Chinese Consensus on the Comprehensive Management of Alzheimer's Disease. Neurosci Bull 2021; 37:1025-1038. [PMID: 34050523 PMCID: PMC8275730 DOI: 10.1007/s12264-021-00701-z] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2020] [Accepted: 01/06/2021] [Indexed: 01/05/2023] Open
Abstract
Alzheimer's disease (AD) is the most common cognitive disorder in the elderly. Its main clinical manifestations are cognitive decline (C), behavioral and psychological symptoms (B), and a decline in the activities of daily living (A), also known as ABC symptoms. Early identification and evaluation of ABC symptoms are helpful for establishing the accurate diagnosis, comprehensive treatment, and prognosis of AD. To guide Chinese clinical practice for optimization of the comprehensive management of AD, in 2018, The Academy of Cognitive Disorder of China gathered 22 neurologists and gerontologists in China to build a consensus on the comprehensive management of AD. Based on a review of the evidence, the consensus summarizes the pathogenesis, pathological changes, clinical manifestations, evaluation, diagnosis, drug and non-drug treatment, and patient care for AD. Focus group discussion was used to establish a flowchart of comprehensive ABC management for AD patients. The new consensus provides a feasible AD management process for clinicians.
Collapse
Affiliation(s)
- Jianjun Jia
- Department of Neurology, The Second Medical Center, People's Liberation Army General Hospital, Beijing, 100853, China.
| | - Jun Xu
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China
| | - Jun Liu
- Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China
| | - Yongjun Wang
- Cognitive Impairment Department, Shenzhen Kangning Hospital, Shenzhen, 518118, China
| | - Yanjiang Wang
- Department of Neurology, Daping Hospital, Army Medical University, Chongqing, 400042, China
| | - Yunpeng Cao
- Department of Neurology, The First Hospital of China Medical University, Shenyang, 210112, China
| | - Qihao Guo
- Department of Gerontology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, 200233, China
| | - Qiuming Qu
- Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China
| | - Cuibai Wei
- Department of Neurology, Xuanwu Hospital Capital Medical University, Beijing, 100053, China
| | - Wenshi Wei
- Department of Neurology, Huadong Hospital Affiliated to Fudan University, Shanghai, 200040, China
| | - Junjian Zhang
- Department of Neurology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China
| | - Enyan Yu
- Department of Psychology, Chinese Academy of Sciences Cancer Hospital of the University of the Chinese Academy of Sciences, Hangzhou, 310022, China
| |
Collapse
|
10
|
Pathmanathan K, Robinson PC, Hill CL, Keen HI. The prevalence of gout and hyperuricaemia in Australia: An updated systematic review. Semin Arthritis Rheum 2020; 51:121-128. [PMID: 33360648 DOI: 10.1016/j.semarthrit.2020.12.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Revised: 11/30/2020] [Accepted: 12/07/2020] [Indexed: 12/13/2022]
Abstract
BACKGROUND Gout continues to increase in prevalence in developed countries with Oceanic countries particularly affected. Both gout and hyperuricaemia are associated with the metabolic syndrome and its sequelae. Recently, the Australian Institute for Health and Welfare (AIHW) reported a prevalence rate of 0.8% which appeared incongruous with other published research. Thus, an updated systematic review was undertaken to review the literature on the prevalence of gout and hyperuricaemia in Australia from data published after 2011. METHODS A comprehensive, systematic search was conducted in MEDLINE, Embase and Web of Science in addition to relevant websites to identify research reporting the prevalence of gout and/or hyperuricaemia in Australia from May 2011 until June 2020. Crude gout and hyperuricaemia prevalence data was obtained and presented alongside case ascertainment, time-period, age range and stratified by gender if available. RESULTS 118 full text articles were screened. 12 articles were included for analysis of gout prevalence. 4 articles were identified for the hyperuricaemia analysis. Wide variation in prevalence figures exist largely due study design and sample age range. Studies using a case definition of self-reported diagnosis of gout reported prevalence rates between 4.5% and 6.8%. The remaining studies used either electronic coding data from general practitioners or wastewater estimation of allopurinol consumption and documented adult prevalence rates between 1.5% and 2.9%. Prevalence increases with age, male sex and over time in keeping with global data. Hyperuricaemia prevalence ranged between 10.5% and 16.6% in Caucasian or an Australian representative population. AIHW estimates applied a chronic condition status, defined as current and lasted or expected to last more than six months, to cases of gout in the Australian National Health Survey. This likely results in an under-estimation in reported Australian gout prevalence rates. CONCLUSIONS Gout is highly prevalent in Australia compared to global comparisons and continues to increase over time. Hyperuricaemia prevalence is also high although contemporary data is limited.
Collapse
Affiliation(s)
- K Pathmanathan
- Department of Rheumatology, Fiona Stanley Hospital, Perth, Australia.
| | - Philip C Robinson
- University of Queensland, Faculty of Medicine, Queensland, Australia
| | - C L Hill
- Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia; Discipline of Medicine, University of Adelaide, Adelaide, Australia
| | - H I Keen
- Department of Rheumatology, Fiona Stanley Hospital, Perth, Australia; School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
| |
Collapse
|
11
|
Picton L, Bell JS, George J, Korhonen MJ, Ilomäki J. The changing pattern of statin use in people with dementia: A population-based study. J Clin Lipidol 2020; 15:192-201. [PMID: 33309941 DOI: 10.1016/j.jacl.2020.11.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 11/09/2020] [Accepted: 11/16/2020] [Indexed: 11/16/2022]
Abstract
BACKGROUND After a dementia diagnosis, goals of care are often reassessed, including the use of preventive medications like statins. OBJECTIVE To examine changes in statin use after initiating medication for managing dementia. METHODS A case-crossover study utilizing medication dispensing data from the Australian Pharmaceutical Benefits Scheme (PBS) 10% random sample was conducted. Use of statins was compared in the 12 months pre- and post-initiation (pre-period and post-period) of anti-dementia medications or risperidone for behavioural symptoms of dementia. Individuals aged ≥65 years who had their first dispensing of anti-dementia medication or risperidone between July 2006 and June 2017 and survived ≥12 months after their first supply were included. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for change in statin use in the discordant pairs. RESULTS The cohort (n = 19,809) had a median age of 81 years and 61% were female. Statins were less likely to be used after initiating anti-dementia medication or risperidone (OR 0.50; 95%CI 0.45-0.55). The OR for statin use in the post-period versus the pre-period decreased annually over the 11 years from 1.21; 95%CI 0.84-1.75 in 2006-7 to 0.31; 95%CI 0.24-0.41 in 2016-17 (p for interaction <0.05). CONCLUSION Statins are more likely to be ceased than started after initiating medication for dementia. This may reflect changes in goals of care, or changes in the interpretation of the available evidence for the safety and efficacy of statins in older people living with dementia.
Collapse
Affiliation(s)
- Leonie Picton
- Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
| | - J Simon Bell
- Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| | - Johnson George
- Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| | | | - Jenni Ilomäki
- Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| |
Collapse
|
12
|
Kravvariti E, Kotsani M, Mitsikostas DD, Sfikakis PP. Nocebo phenomena may be enhanced in aging: Implications for clinical practice. Maturitas 2020; 143:10-16. [PMID: 33308614 DOI: 10.1016/j.maturitas.2020.07.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 07/17/2020] [Accepted: 07/21/2020] [Indexed: 11/30/2022]
Abstract
Nocebo effects, denoting unfavourable outcomes after a medical intervention because of negative expectations rather than a direct pharmacologic action, are an important cause of dropout from clinical trials and non-adherence to medication, and may be especially pertinent for older adults. Several characteristics of aging individuals and their medical care have a potential to augment nocebo susceptibility, such as depression and anxiety, neurodegenerative diseases and chronic pain states, adverse healthcare experiences, generic drug use, age-related stereotypes, and strained patient-physician communication. Nocebo-related research in older adults is hindered by under-representation in clinical trials, medical complexity of geriatric patients, and lack of validated tools to accurately assess susceptibility and efficacy of preventive efforts.
Collapse
Affiliation(s)
- E Kravvariti
- Postgraduate Medical Studies in the Physiology of Aging and Geriatric Syndromes, National and Kapodistrian University of Athens' Medical School, Athens, Greece.
| | - M Kotsani
- Université de Lorraine, CHRU-Nancy, Pôle « Maladies du Vieillissement, Gérontologie et Soins Palliatifs », F-54000, Nancy, France
| | - D D Mitsikostas
- First Department of Neurology, Aeginition Hospital, National and Kapodistrian University of Athens' Medical School, Athens, Greece
| | - P P Sfikakis
- Postgraduate Medical Studies in the Physiology of Aging and Geriatric Syndromes, National and Kapodistrian University of Athens' Medical School, Athens, Greece
| |
Collapse
|
13
|
Cacabelos R. Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease. Expert Opin Drug Metab Toxicol 2020; 16:673-701. [PMID: 32520597 DOI: 10.1080/17425255.2020.1779700] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
INTRODUCTION Cholinergic dysfunction, demonstrated in the late 1970s and early 1980s, led to the introduction of acetylcholinesterase inhibitors (AChEIs) in 1993 (Tacrine) to enhance cholinergic neurotransmission as the first line of treatment against Alzheimer's disease (AD). The new generation of AChEIs, represented by Donepezil (1996), Galantamine (2001) and Rivastigmine (2002), is the only treatment for AD to date, together with Memantine (2003). AChEIs are not devoid of side-effects and their cost-effectiveness is limited. An option to optimize the correct use of AChEIs is the implementation of pharmacogenetics (PGx) in the clinical practice. AREAS COVERED (i) The cholinergic system in AD, (ii) principles of AD PGx, (iii) PGx of Donepezil, Galantamine, Rivastigmine, Huperzine and other treatments, and (iv) practical recommendations. EXPERT OPINION The most relevant genes influencing AChEI efficacy and safety are APOE and CYPs. APOE-4 carriers are the worst responders to AChEIs. With the exception of Rivastigmine (UGT2B7, BCHE-K), the other AChEIs are primarily metabolized via CYP2D6, CYP3A4, and UGT enzymes, with involvement of ABC transporters and cholinergic genes (CHAT, ACHE, BCHE, SLC5A7, SLC18A3, CHRNA7) in most ethnic groups. Defective variants may affect the clinical response to AChEIs. PGx geno-phenotyping is highly recommended prior to treatment.
Collapse
Affiliation(s)
- Ramón Cacabelos
- Department of Genomic Medicine, EuroEspes Biomedical Research Center, International Center of Neuroscience and Genomic Medicine , Bergondo, Corunna, Spain
| |
Collapse
|
14
|
Feng W, Halm-Lutterodt NV, Tang H, Mecum A, Mesregah MK, Ma Y, Li H, Zhang F, Wu Z, Yao E, Guo X. Automated MRI-Based Deep Learning Model for Detection of Alzheimer’s Disease Process. Int J Neural Syst 2020; 30:2050032. [DOI: 10.1142/s012906572050032x] [Citation(s) in RCA: 52] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
In the context of neuro-pathological disorders, neuroimaging has been widely accepted as a clinical tool for diagnosing patients with Alzheimer’s disease (AD) and mild cognitive impairment (MCI). The advanced deep learning method, a novel brain imaging technique, was applied in this study to evaluate its contribution to improving the diagnostic accuracy of AD. Three-dimensional convolutional neural networks (3D-CNNs) were applied with magnetic resonance imaging (MRI) to execute binary and ternary disease classification models. The dataset from the Alzheimer’s disease neuroimaging initiative (ADNI) was used to compare the deep learning performances across 3D-CNN, 3D-CNN-support vector machine (SVM) and two-dimensional (2D)-CNN models. The outcomes of accuracy with ternary classification for 2D-CNN, 3D-CNN and 3D-CNN-SVM were [Formula: see text]%, [Formula: see text]% and [Formula: see text]% respectively. The 3D-CNN-SVM yielded a ternary classification accuracy of 93.71%, 96.82% and 96.73% for NC, MCI and AD diagnoses, respectively. Furthermore, 3D-CNN-SVM showed the best performance for binary classification. Our study indicated that ‘NC versus MCI’ showed accuracy, sensitivity and specificity of 98.90%, 98.90% and 98.80%; ‘NC versus AD’ showed accuracy, sensitivity and specificity of 99.10%, 99.80% and 98.40%; and ‘MCI versus AD’ showed accuracy, sensitivity and specificity of 89.40%, 86.70% and 84.00%, respectively. This study clearly demonstrates that 3D-CNN-SVM yields better performance with MRI compared to currently utilized deep learning methods. In addition, 3D-CNN-SVM proved to be efficient without having to manually perform any prior feature extraction and is totally independent of the variability of imaging protocols and scanners. This suggests that it can potentially be exploited by untrained operators and extended to virtual patient imaging data. Furthermore, owing to the safety, noninvasiveness and nonirradiative properties of the MRI modality, 3D-CNN-SMV may serve as an effective screening option for AD in the general population. This study holds value in distinguishing AD and MCI subjects from normal controls and to improve value-based care of patients in clinical practice.
Collapse
Affiliation(s)
- Wei Feng
- Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, You’anmenwai, Xitoutiao No.10, Beijing, P. R. China
- Beijing Municipal Key Laboratory of Clinical Epidemiology, Capital Medical University, Beijing, P. R. China
| | - Nicholas Van Halm-Lutterodt
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, P. R. China
- Department of Orthopaedics and Neurosurgery, Keck Medical Center of USC, Los Angeles, CA, USA
| | - Hao Tang
- School of Computer Science and Technology, University of the Chinese Academy of Sciences, Beijing, P. R. China
| | - Andrew Mecum
- Department of Psychology, Emory University, Atlanta, GA, USA
| | - Mohamed Kamal Mesregah
- Department of Orthopaedics and Neurosurgery, Keck Medical Center of USC, Los Angeles, CA, USA
| | - Yuan Ma
- Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, You’anmenwai, Xitoutiao No.10, Beijing, P. R. China
- Beijing Municipal Key Laboratory of Clinical Epidemiology, Capital Medical University, Beijing, P. R. China
| | - Haibin Li
- Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, You’anmenwai, Xitoutiao No.10, Beijing, P. R. China
- Beijing Municipal Key Laboratory of Clinical Epidemiology, Capital Medical University, Beijing, P. R. China
| | - Feng Zhang
- Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, You’anmenwai, Xitoutiao No.10, Beijing, P. R. China
- Beijing Municipal Key Laboratory of Clinical Epidemiology, Capital Medical University, Beijing, P. R. China
| | - Zhiyuan Wu
- Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, You’anmenwai, Xitoutiao No.10, Beijing, P. R. China
- Beijing Municipal Key Laboratory of Clinical Epidemiology, Capital Medical University, Beijing, P. R. China
| | - Erlin Yao
- School of Computer Science and Technology, University of the Chinese Academy of Sciences, Beijing, P. R. China
| | - Xiuhua Guo
- Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, You’anmenwai, Xitoutiao No.10, Beijing, P. R. China
- Beijing Municipal Key Laboratory of Clinical Epidemiology, Capital Medical University, Beijing, P. R. China
| |
Collapse
|